Boston Scientific Corporation
BSX
Rang in aandelen
#409
Deze bedrijfsbeschrijving is alleen in het Engels beschikbaar.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Aandeelprijs
$41.88
Laatst gesynchroniseerd: 2026-10-30
Marktkapitalisatie
$60.69B
Verandering (1 dag)
-1.89%
Verandering (1 jaar)
-58.42%
Land
US
Aandelendata: Financial Modeling Prep·Bijgewerkt op ·Geen beleggingsadvies·Zo rekenen we
Handel Boston Scientific Corporation (BSX)
Categorie
Healthcare
Winst voor Boston Scientific Corporation (BSX)
Winst in Sep 2026 TTM: $3.66B
Volgens de meest recente financiële verslagen van Boston Scientific Corporation bedraagt de huidige winst van het bedrijf $3.66B. In 2025 behaalde het bedrijf een winst van $3.39B, een stijging ten opzichte van de winst van 2024, die $2.28B bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Boston Scientific Corporation van 2000 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Verandering |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Vragen over de nettowinst van Boston Scientific Corporation
Wat is de nettowinst van Boston Scientific Corporation?
Per sep. 2026 bedraagt de nettowinst van Boston Scientific Corporation over de afgelopen twaalf maanden $3.66B.
Wat was de nettowinst van Boston Scientific Corporation in 2025?
In 2025 bedroeg de nettowinst van Boston Scientific Corporation $3.39B, 48.33% hoger dan in 2024 ($2.28B).
Hoe heeft de nettowinst van Boston Scientific Corporation zich sinds 2020 ontwikkeld?
Tussen 2020 en 2025 was de nettowinst van Boston Scientific Corporation het hoogst in 2025 ($3.39B) en het laagst in 2020 ($-79.00M).
Hoe verhoudt de nettowinst van Boston Scientific Corporation zich tot vergelijkbare bedrijven?
Bij Boston Scientific Corporation is de nettowinst ($3.66B) hoger dan bij 2 van de 5 vergelijkbare bedrijven in de lijst hierboven. Van die bedrijven heeft Medtronic plc de hoogste waarde: $6.60B.